The deal gives Gilead an estimated 13% ownership in Arcellx and extends the company’s cash runway into 2027.
News Ticker
- [ December 9, 2023 ] New Data Reinforce the Benefit of Early Preventative Treatment With Genentech’s Hemlibra (emicizumab-kxwh) for Babies With Severe hemophilia A News
- [ December 9, 2023 ] AbbVie’s $8.7B neuro gambit; Landmark sickle cell approvals; Roche buys a GLP-1 company; Endpoints 100 biotech survey; and more News
- [ December 9, 2023 ] Research Scientist II, Assay Development – Exact Sciences Corporation – Redwood City, CA San Francisco Biotech Jobs
- [ December 9, 2023 ] Chemist – Katalyst Healthcares & Life Sciences – Belmont, CA San Francisco Biotech Jobs
- [ December 9, 2023 ] Associate Director/Director, Biostatistics – FibroGen, Inc. – San Francisco, CA San Francisco Biotech Jobs
Copyright © 2023 Biotech Networks, LLC
